Nephrology, primary care, cardiology, endocrinology: if your patient has kidney disease, hypertension, or cardiorenal risk, there may be a protocol for them here, with study-related care handled by us and every result reported back to you.
SCRI is run by the same board-certified nephrologists who practice at Nephrology Associates, PC, the region's premier site for kidney studies. We know what a specialist referral should feel like from your side of the fax machine.
Physician-to-physician updates at screening, enrollment, and closeout. You are never left wondering whether your patient qualified.
Study participation runs alongside their regular care. We manage the study-related visits only; everything else continues in your office.
Study visits, tests, and the investigational therapy are provided at no charge. Insurance is never billed for study-related care.
Every protocol is approved and monitored by an Institutional Review Board before a participant is enrolled.
GCP-trained, ACRP-certified research coordinators, a dedicated regulatory specialist, and on-site pharmacy and lab management.
Board-certified nephrologists published in NEJM and leading journals (SPRINT, DAPA-CKD, vadadustat), several serving as medical directors of area dialysis centers.
Send us the clinical picture. We match it against every open protocol, contact the patient with your knowledge, and report the outcome to your office.
Use the form below, call the study team, or fax the clinical summary to (706) 722-5843. Keep identifiers off the web form. Fax or phone those.
A coordinator reviews the history against current inclusion criteria and calls the patient to explain the study and answer questions.
Whether the patient enrolls or not, your office hears back directly. Enrolled patients continue seeing you for everything outside the protocol.
Populations are as stated by each sponsor. Final eligibility is confirmed by the study team against the full protocol.
Enrolling nowPraliciguat · Phase 2 · NCT07268638
Praliciguat, an oral sGC stimulator, in adults with primary focal segmental glomerulosclerosis whose protein leak persists on a maximally tolerated ACE inhibitor or ARB.
Who it is forAdults with biopsy-confirmed primary FSGS, a urine protein-to-creatinine ratio of 1 g/g or more on a maximally tolerated ACE inhibitor or ARB, and eGFR of 25 or above.
Enrolling nowAZD2373 · Phase 2 · NCT06824987
AZD2373 in adults with APOL1-mediated kidney disease (AMKD) who carry two high-risk APOL1 variants (G1 and G2), measured by the change in urine albumin at 30 weeks (APPRECIATE).
Who it is forAdults 18 to 70 of African descent with a high-risk APOL1 genotype, a urine albumin-to-creatinine ratio of 300 mg/g or more, and eGFR of 25 or above.
Enrolling nowMuvalaplin · Phase 3 · NCT07157774
Muvalaplin, an oral lipoprotein(a) inhibitor, for reducing heart attack and stroke risk in adults with high Lp(a) who have cardiovascular disease or are at risk of a first event (MOVE-Lp(a)).
Who it is forAdults with Lp(a) of 175 nmol/L or more who have had a cardiovascular event, or are at high risk of one, including reduced kidney function with diabetes.
Opening soon: ADPKD (Novartis) and Obesity with type 2 diabetes (Eli Lilly). Broader experience across CKD, diabetic kidney disease, IgA nephropathy, anemia of CKD, polycystic kidney disease, resistant hypertension, and dialysis. See the completed-study history.
Clinical context only on this form: no names, dates of birth, or record numbers. We will call your office to coordinate the rest, or you can fax the summary directly.
Every investigator sees patients at Nephrology Associates, PC. Your patient is evaluated by a specialist, not a study desk.
Former Professor of Medicine at the Medical College of Georgia and a SPRINT site investigator, published in the New England Journal of Medicine on intensive blood-pressure control and chronic kidney disease. A Fellow of both the American Society of Nephrology and the American College of Physicians, he directs every study SCRI runs.
Tell us a little about your kidney health and we will call you back. It costs nothing to ask.
Start here →We screen against every open protocol and report the outcome back to your office, either way.
Refer now →Call to discuss feasibility with a site that has delivered kidney trials for more than 25 years.
Call (706) 922-3005 →Southeastern Clinical Research Institute, LLC · 1521 Anthony Road, Augusta, Georgia 30904 · (706) 922-3005 · Fax (706) 722-5843